瑞博西利联合氟维司群治疗HR阳性/HER2阴性晚期乳腺癌的III期随机研究:MONALEESA-3
MONALEESA-3是一项III期随机研究,评估瑞博西利联合氟维司群用于HR阳性/HER2阴性晚期乳腺癌患者(晚期阶段未接受治疗或仅接受过一线内分泌治疗)。结果显示,瑞博西利联合氟维司群较安慰剂联合氟维司群显著改善中位无进展生存期(20.5个月 vs 12.8个月;HR 0.593;
要点
- 瑞博西利联合氟维司群显著延长中位PFS(20.5 vs 12.8个月;HR 0.593)。
- 初治和经一线内分泌治疗患者中均观察到一致的PFS获益。
- 常见3级不良事件为中性粒细胞减少(46.6% vs 0%)和白细胞减少(13.5% vs 0%)。
核心结论
- 瑞博西利联合氟维司群可能成为HR阳性/HER2阴性晚期乳腺癌的新一线或二线治疗选择。
研究设计与样本
- III期随机研究,纳入HR阳性/HER2阴性晚期乳腺癌患者,按2:1随机分配至瑞博西利联合氟维司群组(484例)或安慰剂联合氟维司群组(242例)。
主要发现
- 晚期阶段未接受治疗患者中HR为0.577(95%CI 0.415-0.802),接受过一线内分泌治疗患者中HR为0.565(95%CI 0.428-0.744)。
- 可测量疾病患者中,瑞博西利联合氟维司群组客观缓解率为40.9%,安慰剂联合氟维司群组为28.7%。
- ≥10%患者报告的3级不良事件(瑞博西利联合氟维司群 vs 安慰剂联合氟维司群):中性粒细胞减少(46.6% vs 0%)、白细胞减少(13.5% vs 0%)。
- ≥5%患者报告的4级事件仅为中性粒细胞减少(6.8% vs 0%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 484 postmenopausal women were randomly assigned to ribociclib plus fulvestrant, and 242 were assigned to placebo plus fulvestrant. Median progression-free survival was significantly improved with ribociclib plus fulvestrant versus placebo plus fulvestrant: 20.5 months (95% CI, 18.5 to 23.5 months) versus 12.8 months (95% CI, 10.9 to 16.3 months), respectively (hazard ratio, 0.593; 95% CI, 0.480 to 0.732; P < .001). Consistent treatment effects were observed in patients who were treatment naïve in the advanced setting (hazard ratio, 0.577; 95% CI, 0.415 to 0.802), as well as in patients who had received up to one line of prior endocrine therapy for advanced disease (hazard ratio, 0.565; 95% CI, 0.428 to 0.744). Among patients with measurable disease, the overall response rate was 40.9% for the ribociclib plus fulvestrant arm and 28.7% for placebo plus fulvestrant. Grade 3 adverse events reported in ≥ 10% of patients in either arm (ribociclib plus fulvestrant v placebo plus fulvestrant) were neutropenia (46.6% v 0%) and leukopenia (13.5% v 0%); the only grade 4 event reported in ≥ 5% of patients was neutropenia (6.8% v 0%). Conclusion Ribociclib plus fulvestrant might represent a new first- or second-line treatment option in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
引用
- Slamon DJ, Neven P, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018. PMID: 29860922. doi:10.1200/JCO.2018.78.9909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。